Claims for Patent: 10,011,592

Summary for Patent: 10,011,592

Title:	Polycyclic inhibitor of anaplastic lymphoma kinase
Abstract:	Disclosed is a polycyclic inhibitor of anaplastic lymphoma kinase as represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof. Also disclosed is a method for preparing the compound, a pharmaceutical preparation and a pharmaceutical composition comprising the compound, and use of the compound, the pharmaceutically acceptable salt or stereoisomer thereof in manufacture of a medicament for the treatment and/or prevention of, for example, an anaplastic lymphoma kinase-mediated cancer or non-cancer related diseases.
Inventor(s):	Wu; Frank (Shandong, CN)
Assignee:	XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN)
Application Number:	15/515,056
Patent Claims:	1. A compound of Formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof: ##STR00086## wherein, R.sup.1 is selected from the group consisting of --SO.sub.2R.sup.5 and --SO.sub.2NRR.sup.5; R.sup.2 is selected from the group consisting of hydrogen atom, halogen atom, nitro, cyano, amino, hydroxyl, carboxyl and C.sub.1-6alkyl; R.sup.3 is selected from the group consisting of 5-6 membered heteroaryl containing 1-2 N atom(s) that is optionally substituted with 1-2 substituent(s) W, and 4-6 membered heterocyclyl containing 1-2 N atom(s) that is optionally substituted with 1-2 substituent(s) W, W is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkylamino, (C.sub.1-6alkyl).sub.2amino, halo-C.sub.1-6alkyl, halo-C.sub.1-6alkoxy, C.sub.1-6alkylcarbonyl, C.sub.1-6alkylcarbonyloxy and C.sub.1-6alkylsulfonyl; R.sup.4 is selected from the group consisting of hydrogen atom, halogen atom, cyano, nitro, amino, hydroxyl, carboxyl, C.sub.1-6alkoxy, C.sub.1-6alkyl, halo-C.sub.1-6alkyl, C.sub.1-6alkylamino, C.sub.1-6alkylcarbonyl and C.sub.1-6alkylcarbonyloxy; R and R.sup.5 are independently selected from the group consisting of hydrogen atom and C.sub.1-6alkyl; A is selected from the group consisting of 5 membered heterocyclyl containing two O atoms that is optionally substituted with 1-2 substituent(s) Q, and 6 membered heterocyclyl containing two O atoms that is optionally substituted with 1-2 substituent(s) Q; the substituent Q is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom and C.sub.1-6alkyl. 2. The compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, wherein, R.sup.1 is selected from the group consisting of --SO.sub.2R.sup.5 and --SO.sub.2NRR.sup.5; R.sup.2 is selected from the group consisting of hydrogen atom, halogen atom, nitro, cyano, amino, hydroxyl, carboxyl and C.sub.1-4alkyl; R.sup.3 is selected from 4-6 membered heterocyclyl containing 1-2 N atom(s) that is optionally substituted with 1-2 substituent(s) W; W is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom, C.sub.1-4alkyl, C.sub.1-4alkoxy, C.sub.1-4alkylamino, (C.sub.1-4alkyl).sub.2amino, halo-C.sub.1-4alkyl, halo-C.sub.1-4alkoxy, C.sub.1-4alkylcarbonyl, C.sub.1-4alkylcarbonyloxy and C.sub.1-4alkylsulfonyl; R.sup.4 is selected from the group consisting of fluorine atom, bromine atom and chlorine atom; R and R.sup.5 are independently selected from C.sub.1-4alkyl; A is selected from the group consisting of 5 membered heterocyclyl containing two O atoms and 6 membered heterocyclyl containing two O atoms, optionally substituted with one substituent Q; the substituent Q is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom and C.sub.1-4alkyl. 3. The compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, wherein, R.sup.1 is selected from the group consisting of --SO.sub.2R.sup.5 and --SO.sub.2NRR.sup.5; R.sup.2 is selected from the group consisting of hydrogen atom, halogen atom, nitro, cyano, amino, hydroxyl, carboxyl and C.sub.1-4alkyl; R.sup.3 is selected from the group consisting of pyridinyl, dihydropyridinyl, tetrahydropyridinyl, azetidinyl, pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl, pyrazolyl, dihydropyrazolyl, tetrahydropyrazolyl, imidazolyl, dihydroimidazolyl, tetrahydroimidazolyl, pyrimidinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, piperidyl, piperazinyl and morpholinyl; R.sup.4 is selected from the group consisting of fluorine atom, bromine atom and chlorine atom; R and R.sup.5 are independently selected from C.sub.1-4alkyl; A is selected from the group consisting of 5 membered heterocyclyl containing two oxygen atoms and 6 membered heterocyclyl containing 2 oxygen atoms, optionally substituted with one substituent Q; the substituent Q is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom and C.sub.1-4alkyl. 4. The compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 3, wherein, R.sup.1 is selected from the group consisting of --SO.sub.2R.sup.5 and --SO.sub.2NRR.sup.5; R.sup.2 is selected from the group consisting of hydrogen atom, halogen atom, nitro, cyano, amino, hydroxyl, carboxyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; R.sup.3 is selected from the group consisting of pyridinyl, dihydropyridinyl, tetrahydropyridinyl, pyrrolyl, dihydropyrrolyl, tetrahydropyrrolyl, azetidinyl, piperidyl, piperazinyl and morpholinyl; R.sup.4 is selected from the group consisting of fluorine atom, bromine atom and chlorine atom; R and R.sup.5 are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; A is a 6 membered heterocyclyl containing two oxygen atoms, optionally substituted with one substituent Q, the substituent Q is selected from the group consisting of hydroxyl, amino, carboxyl, cyano, nitro, halogen atom, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl. 5. The compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, wherein the compound is selected from the group consisting of: ##STR00087## 6. A pharmaceutical preparation, prepared from the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, and one or more pharmaceutically acceptable carriers and/or diluents, in any pharmaceutically acceptable dosage form. 7. A pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, further comprising one or more antitumor agents and/or immunosuppressors. 8. The pharmaceutical composition according to claim 7, wherein the antitumor agent and/or immunosuppressor is an antimetabolite, selected from the group consisting of capecitabine, gemcitabine and pemetrexed disodium; or the antitumor agent and/or immunosuppressor is a growth factor inhibitor, selected from the group consisting of pazopanib, imatinib, erlotinib, lapatinib, gefitinib and vandetanib; or the antitumor agent and/or immunosuppressor is an antibody, selected from the group consisting of herceptin and bevacizumab; or the antitumor agent and/or immunosuppressor is amitotic inhibitor, selected from the group consisting of paclitaxel, vinorelbine, docetaxel and doxorubicin; or the antitumor agent and/or immunosuppressor is an antitumor hormone, selected from the group consisting of letrozole, tamoxifen, fulvestrant, flutamide and triptorelin; or the antitumor agent and/or immunosuppressor is an alkylating agent, selected from the group consisting of cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, carmustine and temozolomide; or the antitumor agent and/or immunosuppressor is a metallic platinum, selected from the group consisting of carboplatin, cisplatin and oxaliplatin; or the antitumor agent and/or immunosuppressor is an immunosuppressor, selected from the group consisting of everolimus, sirolimus and temsirolimus; or the antitumor agent and/or immunosuppressor is a purine analog, selected from the group consisting of 6-mercaptopurine, 6-thioguanine and azathioprine; or the antitumor agent and/or immunosuppressor is an antibiotic, selected from the group consisting of Actinomycin D, daunorubicin, doxorubicin, mitoxantrone, bleomycin and plicamycin; or the antitumor agent and/or immunosuppressor is a platinum complex, selected from the group consisting of cisplatin and carboplatin; or the antitumor agent and/or immunosuppressor is an adrenocortical inhibitor, selected from aminoglutethimide; or the antitumor agent and/or immunosuppressor is an enzyme inhibitor, selected from the group consisting of cytarabine, methotrexate, hydroxyurea, hydroxycamptothecin, camptothecin, topotecan andirinotecan. 9. A method for treating an ALK-mediated cancer or non-cancer related disease, comprising administering to a patient in need thereof the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 1, or a pharmaceutical composition comprising said compound, or the pharmaceutically acceptable salt or stereoisomer thereof, wherein the cancer related disease is selected from the group consisting of brain carcinoma, lung cancer, squamous cell cancer, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, esophageal adenocarcinoma, esophageal squamous cancer, non-Hodgkin lymphoma, central nervous system tumor, prostatic cancer, thyroid cancer, small cell lung cancer, female reproductive duct cancer, cancer in situ, lymphoma, neurofibromatosis, osteocarcinoma, skin cancer, colon cancer, testiculus cancer, non-small cell lung cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, astrocytoma, neuroblastoma and sarcoma; the non-cancer related disease is selected from benign hyperplasia of skin or prostate. 10. A method for treating an ALK-mediated cancer or non-cancer related disease, comprising administering to a patient in need thereof the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 2, or a pharmaceutical composition comprising said compound, or the pharmaceutically acceptable salt or stereoisomer thereof, wherein the cancer related disease is selected from the group consisting of brain carcinoma, lung cancer, squamous cell cancer, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, esophageal adenocarcinoma, esophageal squamous cancer, non-Hodgkin lymphoma, central nervous system tumor, prostatic cancer, thyroid cancer, small cell lung cancer, female reproductive duct cancer, cancer in situ, lymphoma, neurofibromatosis, osteocarcinoma, skin cancer, colon cancer, testiculus cancer, non-small cell lung cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, astrocytoma, neuroblastoma and sarcoma; the non-cancer related disease is selected from benign hyperplasia of skin or prostate. 11. A method for treating an ALK-mediated cancer or non-cancer related disease, comprising administering to a patient in need thereof the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 3, or a pharmaceutical composition comprising said compound, or the pharmaceutically acceptable salt or stereoisomer thereof, wherein the cancer related disease is selected from the group consisting of brain carcinoma, lung cancer, squamous cell cancer, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, esophageal adenocarcinoma, esophageal squamous cancer, non-Hodgkin lymphoma, central nervous system tumor, prostatic cancer, thyroid cancer, small cell lung cancer, female reproductive duct cancer, cancer in situ, lymphoma, neurofibromatosis, osteocarcinoma, skin cancer, colon cancer, testiculus cancer, non-small cell lung cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, astrocytoma, neuroblastoma and sarcoma; the non-cancer related disease is selected from benign hyperplasia of skin or prostate. 12. A method for treating an ALK-mediated cancer or non-cancer related disease, comprising administering to a patient in need thereof the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 4, or a pharmaceutical composition comprising said compound, or the pharmaceutically acceptable salt or stereoisomer thereof, wherein the cancer related disease is selected from the group consisting of brain carcinoma, lung cancer, squamous cell cancer, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, esophageal adenocarcinoma, esophageal squamous cancer, non-Hodgkin lymphoma, central nervous system tumor, prostatic cancer, thyroid cancer, small cell lung cancer, female reproductive duct cancer, cancer in situ, lymphoma, neurofibromatosis, osteocarcinoma, skin cancer, colon cancer, testiculus cancer, non-small cell lung cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, astrocytoma, neuroblastoma and sarcoma; the non-cancer related disease is selected from benign hyperplasia of skin or prostate. 13. A method for treating an ALK-mediated cancer or non-cancer related disease, comprising administering to a patient in need thereof the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 5, or a pharmaceutical composition comprising said compound, or the pharmaceutically acceptable salt or stereoisomer thereof, wherein the cancer related disease is selected from the group consisting of brain carcinoma, lung cancer, squamous cell cancer, bladder carcinoma, gastric cancer, ovarian cancer, peritoneal carcinoma, pancreatic carcinoma, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, renal carcinoma, esophageal adenocarcinoma, esophageal squamous cancer, non-Hodgkin lymphoma, central nervous system tumor, prostatic cancer, thyroid cancer, small cell lung cancer, female reproductive duct cancer, cancer in situ, lymphoma, neurofibromatosis, osteocarcinoma, skin cancer, colon cancer, testiculus cancer, non-small cell lung cancer, gastrointestinal stromal tumor, mast cell tumor, multiple myeloma, melanoma, glioma, astrocytoma, neuroblastoma and sarcoma; the non-cancer related disease is selected from benign hyperplasia of skin or prostate. 14. A pharmaceutical preparation, prepared from the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 5, and one or more pharmaceutically acceptable carriers and/or diluents, in any pharmaceutically acceptable dosage form. 15. A pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt or stereoisomer thereof according to claim 5, further comprising one or more antitumor agents and/or immunosuppressors.

Details for Patent 10,011,592

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	10,011,592	2034-09-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	10,011,592	2034-09-29
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004	10,011,592	2034-09-29